Implication of Metformin Plus Aromatase Inhibitor in Obese Postmenopausal Breast Cancer Women
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Metformin is an anti-diabetic oral hypoglycemic agent that considered the gold standard
therapy for the treatment of type 2 diabetes. Retrospective analyses show that metformin can
offer therapeutic benefits to patients with several forms of cancer. It also has positive
weight reducing effect on non-diabetic patient by improving insulin sensitivity (although the
exact underlying pathomechanisms remain to be elucidated).